To assess the potential relevance of MEK and/or mTOR inhibition in ccRCC we examined reverse phase protein array data (RPPA) from the TCGA clear cell kidney cancer project (KIRC) to determine the relative activation state of these pathways in human RCC [39]. The gene discussed is MTOR; the disease is renal cell carcinoma.